FDA Clears BD Diagnostics' MRSA Assay | GenomeWeb

NEW YORK (GenomeWeb News) – BD Diagnostics, a segment of Becton Dickinson, today announced that the US Food and Drug Administration has cleared the BD Max MRSA molecular test for marketing in the US.

The assay runs on the fully automated BD Max System and was developed to rapidly identify patients with methicillin-resistant Staphylococcus aureus.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.